54
Participants
Start Date
July 31, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
TQB2916 injection + doxorubicin hydrochloride for injection
"TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells."
TQB2916 injection+penpulimab injection
TQB2916 is a humanized IgG2 monoclonal antibody targeting CD40. Penpulimab injection is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor.
Cancer Hospital Chinese Academy of Medical Science, Beijing
Beijing Cancer Hospital, Beijing
Jilin Cancer Hospital, Changchun
Fudan University Shanghai Cancer Center, Shanghai
Cancer Hospital Affiliated to Shandong First Medical University, Jinan
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Zhe Jiang Cancer Hospital, Hangzhou
Hunan Cancer Hospital, Changsha
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou
Xinjiang Medical University Affiliated Cancer Hospital, Ürümqi
Shanxi Cancer Hospital, Taiyuan
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY